XBIT logo

XBiotech (XBIT) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 April 2015

Indexes:

Not included

Description:

XBiotech is a biotechnology company focused on developing innovative therapies for cancer and other diseases. They use a unique approach to create treatments based on human antibodies, aiming to improve patient outcomes and provide effective solutions in the field of medicine.

Events Calendar

Earnings

Next earnings date:

May 09, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

July 15, 2021
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

07 Apr '20 Piper Sandler
Overweight
11 Dec '19 PiperJaffray
Overweight
11 Dec '19 Piper Sandler
Overweight
14 June '19 Piper Sandler
Overweight
14 June '19 Piper Jaffray
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
XBIT
accesswire.com03 January 2025

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
XBIT
prnewswire.com02 January 2025

NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
XBIT
accesswire.com02 January 2025

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.

XBiotech Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - XBIT
XBiotech Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - XBIT
XBiotech Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - XBIT
XBIT
accesswire.com31 December 2024

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
XBIT
accesswire.com31 December 2024

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Shareholders that Lost Money on XBiotech Inc. (XBIT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - XBIT
Shareholders that Lost Money on XBiotech Inc. (XBIT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - XBIT
Shareholders that Lost Money on XBiotech Inc. (XBIT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - XBIT
XBIT
accesswire.com30 December 2024

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
XBIT
accesswire.com30 December 2024

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

An Investigation Has Commenced on Behalf of XBiotech Inc. Shareholders. Contact Levi & Korsinsky to Discuss your XBIT Losses.
An Investigation Has Commenced on Behalf of XBiotech Inc. Shareholders. Contact Levi & Korsinsky to Discuss your XBIT Losses.
An Investigation Has Commenced on Behalf of XBiotech Inc. Shareholders. Contact Levi & Korsinsky to Discuss your XBIT Losses.
XBIT
accesswire.com29 December 2024

NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
XBIT
accesswire.com29 December 2024

NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

XBIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by XBiotech Inc.
XBIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by XBiotech Inc.
XBIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by XBiotech Inc.
XBIT
accesswire.com27 December 2024

NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of XBiotech?
  • What is the ticker symbol for XBiotech?
  • Does XBiotech pay dividends?
  • What sector is XBiotech in?
  • What industry is XBiotech in?
  • What country is XBiotech based in?
  • When did XBiotech go public?
  • Is XBiotech in the S&P 500?
  • Is XBiotech in the NASDAQ 100?
  • Is XBiotech in the Dow Jones?
  • When was XBiotech's last earnings report?
  • When does XBiotech report earnings?
  • Should I buy XBiotech stock now?

What is the primary business of XBiotech?

XBiotech is a biotechnology company focused on developing innovative therapies for cancer and other diseases. They use a unique approach to create treatments based on human antibodies, aiming to improve patient outcomes and provide effective solutions in the field of medicine.

What is the ticker symbol for XBiotech?

The ticker symbol for XBiotech is NASDAQ:XBIT

Does XBiotech pay dividends?

No, XBiotech does not pay dividends

What sector is XBiotech in?

XBiotech is in the Healthcare sector

What industry is XBiotech in?

XBiotech is in the Biotechnology industry

What country is XBiotech based in?

XBiotech is headquartered in United States

When did XBiotech go public?

XBiotech's initial public offering (IPO) was on 15 April 2015

Is XBiotech in the S&P 500?

No, XBiotech is not included in the S&P 500 index

Is XBiotech in the NASDAQ 100?

No, XBiotech is not included in the NASDAQ 100 index

Is XBiotech in the Dow Jones?

No, XBiotech is not included in the Dow Jones index

When was XBiotech's last earnings report?

XBiotech's most recent earnings report was on 13 November 2024

When does XBiotech report earnings?

The next expected earnings date for XBiotech is 9 May 2025

Should I buy XBiotech stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions